CN1628104A - 喹唑啉酮衍生物及其作为cb激动剂的应用 - Google Patents
喹唑啉酮衍生物及其作为cb激动剂的应用 Download PDFInfo
- Publication number
- CN1628104A CN1628104A CNA038034484A CN03803448A CN1628104A CN 1628104 A CN1628104 A CN 1628104A CN A038034484 A CNA038034484 A CN A038034484A CN 03803448 A CN03803448 A CN 03803448A CN 1628104 A CN1628104 A CN 1628104A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- hydroxyl
- formula
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Ex | R1 | R2 | R3 | R4 | R5 | R6a | 离子质量(离子) | RT*[分钟] |
3 | -Cl | -H | -H | -Cl | -H | -CH2CH3 | 492.1[M+] | 6.4 |
4 | -CH2C(O)OCH3 | -H | -H | -H | -H | -CH2CH3 | 496[M+H]+ | 5.37 |
5 | -Cl | -H | -H | -H | -Cl | -CH2CH3 | 492.5[M+H]+ | 6.18 |
6 | -SO2-N(CH3)2 | -H | -H | -H | -H | -CH2CH3 | 531.2[M+H]+ | 5.4 |
7 | -Cl | -Cl | -H | -H | -H | -CH2CH3 | 492.5[M+H]+ | 6.67 |
8 | -SO2-CH3 | -H | -H | -H | -H | -CH2CH3 | 502[M+H]+ | 5.2 |
9 | -S-CH3 | -H | -H | -H | -H | -CH2CH3 | 470[M+H]+ | 6.4 |
10 | -CH=CH-CH=CH- | -H | -H | -CH3 | -CH2CH3 | 488[M+H]+ | 6.5 | |
11 | -H | -Cl | -H | -H | -H | -CH2CH3 | 458[M+H]+ | 4.96 |
12 | -SO2-CH3 | -H | -H | -H | -H | -CH2CH2CH3 | 516[M+H]+ | 5.5 |
13 | -CH=CH-CH=CH- | -H | -H | -H | -CH2CH3 | 474.5[M+H]+ | 6.21 | |
14 | 氰基 | -H | -H | -H | -H | -CH2CH3 | 449.2[M+H]+ | 5.6 |
15 | -S-CH3 | -H | -H | -H | -H | -CH2CH2CH3 | 484[M+H]+ | 6.3 |
16 | -SO-CH3 | -H | -H | -H | -H | -CH2CH3 | 486[M+H]+ | 5.5 |
17 | -CH2CH2-C(O)OCH3 | -H | -H | -H | -H | -CH2CH3 | 510[M+H]+ | 5.6 |
18 | -C(O)OCH3 | -H | -H | -H | -H | -CH2CH3 | 482.5[M+H]+ | 5.55 |
19 | -H | -H | -CH3 | -Cl | -H | -CH2CH3 | 472.1[M+H]+ | 6.4 |
20 | -NH-CH2-CH2-CH2- | -H | -H | -H | -CH2CH3 | 479.1[M+H]+ | 6.1 | |
21 | -C(O)-N(CH3)2 | -H | -H | -H | -H | -CH2CH3 | 495.2[M+H]+ | 5.5 |
22 | -SO2-N(CH3)CH2COOH | -H | -H | -H | -H | -CH2CH3 | 575.2[M+H]+ | 4.8 |
23 | -H | -CH=CH-CH=CH- | -H | -H | -CH2CH3 | 474.5[M+H]+ | 6.3 | |
24 | -H | -CF3 | -H | -H | -H | -CH2CH3 | 492[M+H]+ | 5.15 |
25 | -H | -H | -F | -H | -H | -CH2CH3 | 442[M+H]+ | 6.2 |
Ex | R1 | R2 | R3 | R4 | R5 | R12 | 离子质量(离子) | RT*[分钟] |
26 | -SO2-N-1-吡咯烷基 | -H | -H | -H | -H | -CH2CH2-OH | 573.2[M+H]+ | 4.95 |
27 | -Cl | -H | -H | -H | -H | -CH2CH2-S-CH3 | 504.4[M+] | 6.3 |
28 | -SO2-N(CH3)2 | -H | -H | -H | -H | -CH2CH2-OH | 547[M+H]+ | 4.57 |
29 | -Cl | -H | -H | -H | -H | -CH2CF3 | 512.5[M+H]+ | 6.4 |
30 | -SO2-N(CH3)2 | -H | -H | -H | -H | -CH2CH2CH2-OH | 561[M+H]+ | 4.7 |
31 | -Cl | -H | -H | -H | -H | -CH2-C(O)OCH3 | 502.4[M+H]+ | 5.75 |
32 | -Cl | -H | -H | -H | -Cl | -CH2CH2-SO2-CH3 | 570[M+] | 5.6 |
33 | -Cl | -H | -H | -H | -H | -CH2C(O)NH2 | 487.5[M+H]+ | 4.7 |
Ex | R1 | R2 | R3 | R4 | R5 | R12 | R13 | 离子质量(离子) | RT*[分钟] |
69 | -SO2-N(CH3)2 | -H | -H | -H | -H | -CH2-CH2-CHOH-CH2-CH2- | 587[M+H]+ | 4.9 | |
70 | -SO2-NHCH3 | -H | -H | -H | -H | -CH2-CH2-CHOH-CH2- | 559.4[M+H]+ | 4.8 | |
71 | -SO2-NHCH3 | -H | -H | -H | -H | -CH2-CH2-(R)-CHOH-CH2- | 559.2[M+H]+ | 4.9 | |
72 | -SO2-NHCH3 | -H | -H | -H | -H | -CH2-CH2-C(O)-CH2- | 557.2[M+H]+ | ||
73 | -SO2-NHCH3 | -H | -H | -H | -H | -CH2-CH2-CH2-(R)-CH(CH2OH)- | 573.0[M+H]+ | 5.5 | |
74 | -SO2-NHCH2CH3 | -H | -H | -H | -H | -CH2-(R)-CHOH-CH2-CH2- | 573.2[M+H]+ | 5 | |
75 | -SO2-NHCH3 | -H | -H | -H | -H | -CH2-CH2-(S)-CHOH-CH2- | 559.0[M+H]+ | 5.9 | |
76 | -SO2-NHCH3 | -H | -H | -H | -H | -CH2-CH2-CH2-(S)-CHOH-CH2- | 573.0[M+H]+ | 6.4 |
Claims (13)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0202755.5 | 2002-02-06 | ||
GB0202755A GB0202755D0 (en) | 2002-02-06 | 2002-02-06 | Organic compounds |
GB0213285.0 | 2002-06-10 | ||
GB0213285A GB0213285D0 (en) | 2002-06-10 | 2002-06-10 | Organic compound |
GB0221459.1 | 2002-09-16 | ||
GB0221459A GB0221459D0 (en) | 2002-09-16 | 2002-09-16 | Organic compound |
GB0221460A GB0221460D0 (en) | 2002-09-16 | 2002-09-16 | Organic compound |
GB0221460.9 | 2002-09-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1628104A true CN1628104A (zh) | 2005-06-15 |
CN100579968C CN100579968C (zh) | 2010-01-13 |
Family
ID=27739227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN03803448A Expired - Fee Related CN100579968C (zh) | 2002-02-06 | 2003-02-05 | 喹唑啉酮衍生物及其作为cb激动剂的应用 |
Country Status (22)
Country | Link |
---|---|
US (2) | US20050085493A1 (zh) |
EP (2) | EP2319839A1 (zh) |
JP (2) | JP4428479B2 (zh) |
KR (1) | KR100954626B1 (zh) |
CN (1) | CN100579968C (zh) |
AR (1) | AR038483A1 (zh) |
AT (1) | ATE551329T1 (zh) |
AU (1) | AU2003210212A1 (zh) |
BR (1) | BR0307461A (zh) |
CA (1) | CA2471974C (zh) |
CO (1) | CO5601021A2 (zh) |
EC (1) | ECSP045219A (zh) |
ES (1) | ES2384967T3 (zh) |
HK (1) | HK1079518A1 (zh) |
MX (1) | MXPA04007641A (zh) |
MY (1) | MY143958A (zh) |
NO (1) | NO328305B1 (zh) |
NZ (1) | NZ571615A (zh) |
PE (1) | PE20030867A1 (zh) |
PL (1) | PL370657A1 (zh) |
TW (1) | TW200306839A (zh) |
WO (1) | WO2003066603A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106146414A (zh) * | 2016-07-07 | 2016-11-23 | 浙江大学 | 喹唑啉二酮类衍生物及其制备方法和用途 |
CN106831502A (zh) * | 2017-03-13 | 2017-06-13 | 苏州市泽宸贸易有限公司 | 邻硝基苯磺酰氯、其合成方法及应用 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK287238B6 (sk) | 1999-03-17 | 2010-04-07 | Astrazeneca Ab | Amidové deriváty, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie |
TW200306839A (en) * | 2002-02-06 | 2003-12-01 | Novartis Ag | Quinazolinone derivatives and their use as CB agonists |
GB0324790D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
CN1875021A (zh) | 2003-11-04 | 2006-12-06 | 默克公司 | 取代的萘啶酮衍生物 |
SE0303491D0 (sv) * | 2003-12-19 | 2003-12-19 | Astrazeneca Ab | New use VI |
CN100506802C (zh) * | 2004-06-04 | 2009-07-01 | 中国科学院上海药物研究所 | 一类甲酰肽样受体-1调节剂、其制备方法和用途 |
GB0413618D0 (en) * | 2004-06-17 | 2004-07-21 | Novartis Ag | Organic compounds |
US20090029984A1 (en) * | 2005-07-11 | 2009-01-29 | N.V. Organon | Synergistic combination for the treatment of pain (cannabinoid receptor agonist and opioid receptor agonist) |
GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
WO2008157500A1 (en) * | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
FR2944013B1 (fr) * | 2009-04-07 | 2011-07-15 | Sanofi Aventis | Derives de 1-alkyl-cinnolin-4(1h)-one substitues,leur preparation et leur application en therapeutique. |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体 |
WO2011095450A1 (en) | 2010-02-02 | 2011-08-11 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
AU2013255458A1 (en) | 2012-05-03 | 2014-10-09 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
CN109796360B (zh) * | 2019-01-30 | 2022-03-18 | 上海阿拉丁生化科技股份有限公司 | 一种3-氨基-2-萘甲酸类化合物的制备工艺 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR6200M (zh) | 1967-04-18 | 1968-07-22 | ||
DE1803210A1 (de) | 1968-10-16 | 1970-05-14 | Troponwerke Dinklage & Co | 2-Methyl-3-(3-[4-phenylpiperazinyl-(1)]-2-hydroxypropyl)-chinazolinon-(4) und Verfahren zu seiner Herstellung |
NZ192392A (en) * | 1978-12-19 | 1983-02-15 | M Ishikawa | 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones |
JPS5657768A (en) * | 1979-10-18 | 1981-05-20 | Masayuki Ishikawa | Novel 4-quinazolone derivative substituted by aromatic residue at 3-position |
JPS57118570A (en) * | 1981-01-16 | 1982-07-23 | Masayuki Ishikawa | Novel 3-phenyl-4-quinazolone derivative |
AU543928B2 (en) * | 1981-01-16 | 1985-05-09 | Masayuki Ishikawa | 4(311)-quinazolinone derivatives |
CA2131101A1 (en) * | 1992-05-13 | 1993-11-25 | Louis Desantis Jr. | Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents |
WO1997029079A1 (fr) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Composes chimiques et utilisation pharmaceutique |
TW200306839A (en) | 2002-02-06 | 2003-12-01 | Novartis Ag | Quinazolinone derivatives and their use as CB agonists |
SE0303491D0 (sv) | 2003-12-19 | 2003-12-19 | Astrazeneca Ab | New use VI |
GB0413618D0 (en) * | 2004-06-17 | 2004-07-21 | Novartis Ag | Organic compounds |
-
2003
- 2003-01-30 TW TW092102105A patent/TW200306839A/zh unknown
- 2003-02-04 AR ARP030100347A patent/AR038483A1/es unknown
- 2003-02-04 PE PE2003000129A patent/PE20030867A1/es not_active Application Discontinuation
- 2003-02-05 PL PL03370657A patent/PL370657A1/xx unknown
- 2003-02-05 AU AU2003210212A patent/AU2003210212A1/en not_active Abandoned
- 2003-02-05 EP EP10175740A patent/EP2319839A1/en not_active Withdrawn
- 2003-02-05 MY MYPI20030387A patent/MY143958A/en unknown
- 2003-02-05 EP EP03737316A patent/EP1472234B1/en not_active Expired - Lifetime
- 2003-02-05 CA CA2471974A patent/CA2471974C/en not_active Expired - Fee Related
- 2003-02-05 NZ NZ571615A patent/NZ571615A/en not_active IP Right Cessation
- 2003-02-05 KR KR1020047012147A patent/KR100954626B1/ko not_active IP Right Cessation
- 2003-02-05 ES ES03737316T patent/ES2384967T3/es not_active Expired - Lifetime
- 2003-02-05 MX MXPA04007641A patent/MXPA04007641A/es unknown
- 2003-02-05 WO PCT/EP2003/001140 patent/WO2003066603A1/en active Application Filing
- 2003-02-05 AT AT03737316T patent/ATE551329T1/de active
- 2003-02-05 US US10/503,779 patent/US20050085493A1/en not_active Abandoned
- 2003-02-05 BR BR0307461-7A patent/BR0307461A/pt active Search and Examination
- 2003-02-05 JP JP2003565977A patent/JP4428479B2/ja not_active Expired - Fee Related
- 2003-02-05 CN CN03803448A patent/CN100579968C/zh not_active Expired - Fee Related
-
2004
- 2004-08-04 EC EC2004005219A patent/ECSP045219A/es unknown
- 2004-08-25 CO CO04083224A patent/CO5601021A2/es not_active Application Discontinuation
- 2004-08-27 NO NO20043580A patent/NO328305B1/no not_active IP Right Cessation
-
2005
- 2005-12-14 HK HK05111474.7A patent/HK1079518A1/xx not_active IP Right Cessation
-
2007
- 2007-06-26 US US11/823,315 patent/US8552015B2/en not_active Expired - Fee Related
-
2009
- 2009-01-22 JP JP2009012064A patent/JP2009149658A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106146414A (zh) * | 2016-07-07 | 2016-11-23 | 浙江大学 | 喹唑啉二酮类衍生物及其制备方法和用途 |
CN106831502A (zh) * | 2017-03-13 | 2017-06-13 | 苏州市泽宸贸易有限公司 | 邻硝基苯磺酰氯、其合成方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
HK1079518A1 (en) | 2006-04-07 |
US8552015B2 (en) | 2013-10-08 |
KR20040083501A (ko) | 2004-10-02 |
NO20043580D0 (no) | 2004-08-27 |
MY143958A (en) | 2011-07-29 |
CO5601021A2 (es) | 2006-01-31 |
BR0307461A (pt) | 2004-11-09 |
NO328305B1 (no) | 2010-01-25 |
ECSP045219A (es) | 2004-09-28 |
CA2471974C (en) | 2011-11-22 |
EP1472234A1 (en) | 2004-11-03 |
ES2384967T3 (es) | 2012-07-16 |
KR100954626B1 (ko) | 2010-04-27 |
ATE551329T1 (de) | 2012-04-15 |
MXPA04007641A (es) | 2004-11-10 |
PL370657A1 (en) | 2005-05-30 |
WO2003066603A1 (en) | 2003-08-14 |
AU2003210212A1 (en) | 2003-09-02 |
AR038483A1 (es) | 2005-01-19 |
CN100579968C (zh) | 2010-01-13 |
CA2471974A1 (en) | 2003-08-14 |
EP2319839A1 (en) | 2011-05-11 |
PE20030867A1 (es) | 2003-12-04 |
US20050085493A1 (en) | 2005-04-21 |
EP1472234B1 (en) | 2012-03-28 |
NO20043580L (no) | 2004-09-21 |
JP4428479B2 (ja) | 2010-03-10 |
JP2009149658A (ja) | 2009-07-09 |
NZ571615A (en) | 2010-01-29 |
JP2005522439A (ja) | 2005-07-28 |
US20070265285A1 (en) | 2007-11-15 |
TW200306839A (en) | 2003-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1628104A (zh) | 喹唑啉酮衍生物及其作为cb激动剂的应用 | |
JP6774960B2 (ja) | 二環式キナゾリノン誘導体 | |
CN1157378C (zh) | 喹啉衍生物 | |
CN1259120A (zh) | 钙阻滞类化合物 | |
JP2014509660A (ja) | PDK1キナーゼの阻害剤としての置換3−(1H−ベンゾ{d}イミダゾール−2−イル)−1H−インダゾール類似体 | |
CA2627830A1 (en) | Aminopyrimidines useful as kinase inhibitors | |
CN1474815A (zh) | 4-氨基-喹唑啉 | |
CN1950333A (zh) | 取代的甲基芳基或杂芳基酰胺化合物 | |
CN1835931A (zh) | 作为cfr拮抗剂的四氢喹唑啉衍生物 | |
CN1922150A (zh) | 吲唑衍生物以及含有它们的药物组合物 | |
CN1630633A (zh) | 用作缓激肽拮抗剂的在其甲基上具有取代基的n-联苯甲基氨基环烷烃羧酰胺衍生物 | |
CN1671387A (zh) | 芳基取代的乙内酰脲化合物及其作为钠通道阻滞剂的应用 | |
CA2767064C (fr) | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) | |
CN101312979A (zh) | 用于治疗炎性病症的嘧啶化合物 | |
CN1711249A (zh) | 可用作抗痛觉过敏剂的喹唑啉酮衍生物 | |
CN1882574A (zh) | 吡唑基与咪唑基嘧啶 | |
CN1652789A (zh) | 抑制由α4整合素介导的白细胞粘附的杂芳基化合物 | |
CN1041931C (zh) | [1,2,4]***并[4,3-a]喹喔啉化合物,它们的制备及其应用 | |
CN1768053A (zh) | 吡唑化合物 | |
CN101932574B (zh) | 用于治疗对多巴胺d3受体调节产生反应的病症的1,2,4-三嗪-3,5-二酮化合物 | |
CN1950377A (zh) | 作为ikk抑制剂的噻吩并吡啶类化合物 | |
DE102004046623A1 (de) | Neue Pyrimidin-Derivate und ihre Verwendung | |
CN1087015C (zh) | 吡啶衍生物 | |
CN1245978C (zh) | 含有胃促胰酶抑制剂作为活性成分的预防和治疗各种与嗜酸性粒细胞增多有关的疾病的药物 | |
CN1835753A (zh) | 作为促皮质释放素(cfr)拮抗剂的螺-取代的四氢喹唑啉 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1079518 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1079518 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee |
Owner name: NOVARTIS CO., LTD. Free format text: FORMER NAME: NOVARTIS AG |
|
CP01 | Change in the name or title of a patent holder |
Address after: Basel Patentee after: Novartis Ag Address before: Basel Patentee before: Novartis AG |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100113 Termination date: 20150205 |
|
EXPY | Termination of patent right or utility model |